Industry-Leading, Clinically-Driven Results

• 15% Average Year 1 PMPM Reduction
• 88% physician engagement rate with our clinical collaborations
• 94.1% medication adherence rate
• 99.4% client retention rate

Optimized Drug Mix to Reduce Specialty Drug Costs

• Our clinically-driven pharmacy care model reduces specialty drug costs by optimizing drug mix. This is because comparable, lower cost, non-specialty drugs, biosimilars, and other therapies are recommended if clinically appropriate.
• 90% generic dispensing rate
• 64% therapeutic switch rate

Best-In-Class Service

• Our call center average speed to answer, for example, is 12 seconds.

EmpiRx Health CEO, Danny Sanchez, Open Letter in the New York Times:

In a full-page Open Letter recently published in the New York Times, Danny advocated strongly for the critical steps that must be taken to help plan sponsors lower the costs of prescription drugs while ensuring the health and well-being of your members. Danny also called for:

• Attacking the Drug Cost Problem “At the Pen” – When the physician prescribes the medication for their patients.
• Rethinking PBM Reform – Emphasizing “greater transparency” will not fix the underlying problems of the traditional PBM industry.
• Adopting a “Clinically-Driven” PBM Model – The PBM industry needs to return to its core healthcare mission by putting the pharmacist back in pharmacy benefits management.

Click the button below to check out Danny’s New York Times Open Letter. We hope that once you’ve read it, you will want to join with us in transforming pharmacy care. It’s about time!

​EmpiRx Health is exhibiting at the upcoming IFEBP Conference, November 9 – 13th in San Diego, California! Visit our booth #233, grab an espresso, play Jeopardy to win prizes, and to learn more about our groundbreaking, clinically-driven PBM model that puts pharmacists back at the center of care! We look forward to seeing you in sunny California!

Patient: 63-year-old female

Diagnosis: Osteoporosis

Population Health Management Engine Identified: New therapy, available lower-cost alternatives

• Chart notes indicated patient fear of needles.
• EmpiRx Health pharmacist contacted prescriber and recommended patient switch to oral medication.
• The prescriber agreed with first line therapy, and lower cost option, Alendronate.

Annual Plan Savings: $41,608